We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NBTB:NASDAQNBT Bancorp Inc. Analysis

Data as of 2026-06-26 - not real-time

$49.26

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

NBT Bancorp is trading at $49.26, comfortably above its 20‑day ($47), 50‑day ($45.73) and 200‑day ($43.39) moving averages, confirming a bullish technical backdrop. The 14‑day RSI sits near 67, indicating momentum is strong but edging into overbought territory, while a bullish MACD histogram (+0.14) supports continued upside. The stock holds steady above its near‑term support of $44.74 and just shy of resistance at $49.49, with stable volume and a modest beta of 0.67 suggesting limited market‑wide volatility; however, a 30‑day volatility of roughly 23% and an “Extreme Greed” market sentiment signal heightened short‑term risk.
Fundamentally, NBTB delivered a 21.6% revenue surge and robust profitability (operating margin ~40%, profit margin ~26%), translating to a trailing PE of ~14 versus the industry average of ~17, pointing to relative undervaluation. The company’s balance sheet is strong, featuring $784 M in cash against $366 M of debt and a dividend yield of 3% with a sustainable payout ratio of ~41%. A discounted cash‑flow model places fair value near $114, implying over 30% upside, and analysts collectively rate the stock as a “Buy” with a median target of $49, aligning with the current price.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Price approaching short‑term resistance
  • RSI in overbought zone
  • Strong underlying fundamentals

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant DCF upside relative to market price
  • Continued revenue and earnings growth
  • Attractive dividend yield with sustainable payout

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Low beta and solid balance sheet reduce systemic risk
  • Consistent profitability and high operating margins
  • Undervalued valuation metrics and long‑term growth prospects

Key Metrics & Analysis

Financial Health

Revenue Growth21.60%
Profit Margin26.36%
P/E Ratio13.9
ROE10.55%
ROA1.22%
P/B Ratio1.3
Op. Cash Flow$246.3M
Industry P/E16.9

Technical Analysis

TrendBullish
RSI66.9
Support$44.74
Resistance$49.49
MA 20$47.00
MA 50$45.73
MA 200$43.39
MACDBullish
VolumeStable
Fear & Greed Index86.55

Valuation

Fair Value$114.43
Target Price$49.42
Upside/Downside0.32%
GradeUndervalued
TypeGrowth
Dividend Yield3.00%

Risk Assessment

Beta0.67
Volatility23.29%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.